Details of the Drug Combination

General Information of Drug Combination (ID: DCOS3SZ)

Drug Combination Name
FORMESTANE Aminolevulinic Acid Hydrochloride
Indication
Disease Entry Status REF
Malignant melanoma Investigative [1]
Component Drugs FORMESTANE   DMWIDJK Aminolevulinic Acid Hydrochloride   DMWNHPC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: LOX IMVI
Zero Interaction Potency (ZIP) Score: 6.96
Bliss Independence Score: 6.48
Loewe Additivity Score: 10.18
LHighest Single Agent (HSA) Score: 10.66

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of FORMESTANE
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Withdrawn from market [2]
FORMESTANE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
FORMESTANE Interacts with 5 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Adenylate kinase isoenzyme 1 (AK1) OT614AR3 KAD1_HUMAN Increases ADR [4]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Activity [5]
17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) OT6EBDHM DHB1_HUMAN Decreases Activity [6]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Expression [7]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases Expression [7]
------------------------------------------------------------------------------------
Indication(s) of Aminolevulinic Acid Hydrochloride
Disease Entry ICD 11 Status REF
Actinic keratosis EK90.0 Approved [2]
Aminolevulinic Acid Hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Protoporphyrinogen oxidase (PPOX) TTNFMS9 PPOX_HUMAN Modulator [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC5GHNO DU-145 Investigative [1]
Adenocarcinoma DCREEZQ OVCAR3 Investigative [1]
Adenocarcinoma DCCMIO0 A549 Investigative [1]
Adenocarcinoma DCXC3ZT HCT116 Investigative [1]
Adult T acute lymphoblastic leukemia DCIJ5R8 MOLT-4 Investigative [1]
Astrocytoma DCTY4T4 U251 Investigative [1]
Large cell lung carcinoma DCCAL30 NCI-H460 Investigative [1]
Melanoma DCQWFKN MALME-3M Investigative [1]
Renal cell carcinoma DC2CZ2L SN12C Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98.
4 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
5 Screening of selected pesticides for inhibition of CYP19 aromatase activity in vitro. Toxicol In Vitro. 2000 Jun;14(3):227-34.
6 Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol. 2005 Apr;94(5):461-7.
7 Androgen- and estrogen-receptor mediated activities of 4-hydroxytestosterone, 4-hydroxyandrostenedione and their human metabolites in yeast based assays. Toxicol Lett. 2018 Aug;292:39-45. doi: 10.1016/j.toxlet.2018.04.026. Epub 2018 Apr 24.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.